Lbt Innovations Limited (ASX:LBT)


right-arrow Created with Sketch. 0 (0%)
MCAP $27.46M
Last trade 15.45pm 26/11/2021 20mins delayed

Latest Announcements

24/11/2021LBTLbt Innovations Limited
29/10/2021 Price SensitivePSLBTLbt Innovations Limited
28/10/2021 Price SensitivePSLBTLbt Innovations Limited
27/10/2021LBTLbt Innovations Limited
26/10/2021LBTLbt Innovations Limited
08/10/2021LBTLbt Innovations Limited
01/10/2021LBTLbt Innovations Limited
30/09/2021LBTLbt Innovations Limited

Company Overview

LBT Innovations Limited is an Australia-based medical technology company. The Company is engaged in researching, developing and commercializing technologies for the healthcare and laboratory supply markets. The Company's product pipeline includes The Automated Plate Assessment System for antimicrobial resistance (APAS-AMR), WoundVue, Biofilm, Automated Gram Stain Assessment and MicroStreak. The Company's Automated Plate Assessment System (APAS) Independence is a platform technology that automates culture-plate screening and interpretation. APAS Independence screens, interprets, and sorts these plates, overcoming the bottleneck in lab workflows and freeing up microbiologist's time. Its APAS Analysis Modules are the intelligent image analysis software that works together with the APAS Independence to enable the screening of microbiology culture plates.

LBT in the news

LBT Innovations (LBT) is granted FDA clearance for its culture plate reading…
LBT Innovations (LBT) 50 per cent owned joint venture company, Clever Culture…
LBT Innovations (LBT) will present data from five clinical studies featuring its…
LBT Innovations (LBT) appoints Joanne Moss as the company’s new Chair-Elect as…

Search Previous Announcements